NCT01991067View on ClinicalTrials.gov

Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 28, 2018

Study Completion Date

October 28, 2018

Conditions
Tick Borne Encephalitis
Interventions
BIOLOGICAL

TBE virus vaccine

TBE virus vaccine FSME Immun is used in both arms for the study population and the control group

Trial Locations (1)

1090

Medical University of Vienna, Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Vienna

All Listed Sponsors
collaborator

Austrian Science Fund (FWF)

OTHER

lead

Medical University of Vienna

OTHER

NCT01991067 - Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients | Biotech Hunter | Biotech Hunter